Journal issues > Issue 1, February 2017 > Highlights in acute myeloid leukemia (AML): what is going to change?

Highlights in acute myeloid leukemia (AML): what is going to change?

SUMMARY

The decision making process in AML integrates clinical features, an increasing amount of genetic information and minimal residual disease (MRD) data. Combining these data aims at answering the following questions:

do I treat my patient with an intensive (= curative) or a non intensive (= non-curative) approach ?
do I have therapeutic targets to improve the current treatment?
is there an indication for a stem cell transplantation (SCT), maintenance therapy, etc.

Each new edition of ASH brings some new answers. This was again the case at the 2016 annual ASH meeting.

(BELG J HEMATOL 2017;8(1):29–33)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top